Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
agenT-797 + SOC vs Placebo + SOC in Severe Pneumonia With AHRF
NCT07615010Phase 2Recruiting
- Sponsor
- MiNK Therapeutics
- Start
- May 2026
- Primary completion
- Jun 2027
- Countries
- 2
01
Overview
A Phase 2 trial of agenT-797 in pneumonia, acute respiratory distress syndrome (ARDS), sponsored by MiNK Therapeutics. Started May 2026; status: recruiting.
02
Drugs
agenT-797
03
Conditions
pneumoniaacute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT07615010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07615010.